Vanda Pharmaceuticals | VNDA - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Akebia Therapeutics USD 184.84M 18.4M 2025-12
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Anika Therapeutics USD 41.02M 16.46M 2026-03
Arrowhead Research USD 201.64M 112.94M 2025-12
AstraZeneca USD 7.56B 1.85B 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Heron Therapeutics USD 43.07M 26.55M 2025-09
Insmed USD 510.44M 175.68M 2025-12
J&J USD 21.69B 1.98B 2026-03
Lexicon Pharmaceuticals USD 21.36M 41.52M 2025-06
Ligand Pharmaceuticals USD 174.93M 489.59M 2025-12
Merck USD 5.33B 9.24B 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Moderna USD 1.91B 687M 2026-03
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 984.65M 312.03M 2025-12
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 421M 218.49M 2025-12
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Veracyte USD 362.58M 47M 2025-12